Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
STEGLUJAN (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
STEGLUJAN
Date registered
Evaluation commenced
Decision date
Approval time
235 working days (255)
Active ingredients
ertugliflozin and sitagliptin phosphate monohydrate
Registration type
EOI
Indication
New combination
STEGLUJAN (tablets) now also indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate.